Background: In elderly patients with chronic myeloid leukemia (CML) responsive to imatinib, the incidence of clinically significant (CS) late chronic anemia is still unknown. Materials and Methods: To highlight this issue, we revised retrospectively 81 CML patients aged >60 years treated at our Institution with front-line imatinib for at least 24 months in durable complete cytogenetic response (CCyR). CS late chronic anemia was defined as the presence of persistent (>6 months) and otherwise unexplained Hb levels ≤10 g/dL, which occurred >6 months from imatinib start. Results: A condition of CS late chronic anemia occurred in 22 out of 81 patients (27.2%) at different intervals from imatinib start. Seven out of 22 patients (31.8%) needed packed red cell transfusions during the follow-up. At diagnosis, patients who developed CS late chronic anemia were significantly older and had a lower Hb median level. Six out of 22 patients with CS late chronic anemia received subcutaneous recombinant alpha-erythropoietin (EPO) at the standard dosage of 40,000 IU weekly: all 6 patients achieved an erythroid response. A significantly worse event-free survival (EFS) in patients with untreated CS late chronic anemia was observed (p = 0.012). Conclusions: CS late chronic anemia during long-term treatment with imatinib is a common complication in responsive elderly patients, with worse EFS if untreated. Results with EPO are encouraging, but larger studies are warranted to define its role.

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib / Cesini, L.; Carmosino, I.; Breccia, M.; De Benedittis, D.; Mohamed, S.; De Luca, M. L.; Colafigli, G.; Molica, M.; Scalzulli, E.; Massaro, F.; Mariggio, E.; Rizzo, L.; Loglisci, M. G.; Scamuffa, M. C.; Vozella, F.; Diverio, D.; Mancini, M.; Alimena, G.; Foa, R.; Latagliata, R.. - In: ONCOLOGY RESEARCH AND TREATMENT. - ISSN 2296-5262. - 42:12(2019), pp. 660-664. [10.1159/000502801]

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib

Cesini L.
Primo
;
Carmosino I.;De Luca M. L.;Colafigli G.;Molica M.;Scalzulli E.;Mariggio E.;Vozella F.;Alimena G.;Foa R.;Latagliata R.
2019

Abstract

Background: In elderly patients with chronic myeloid leukemia (CML) responsive to imatinib, the incidence of clinically significant (CS) late chronic anemia is still unknown. Materials and Methods: To highlight this issue, we revised retrospectively 81 CML patients aged >60 years treated at our Institution with front-line imatinib for at least 24 months in durable complete cytogenetic response (CCyR). CS late chronic anemia was defined as the presence of persistent (>6 months) and otherwise unexplained Hb levels ≤10 g/dL, which occurred >6 months from imatinib start. Results: A condition of CS late chronic anemia occurred in 22 out of 81 patients (27.2%) at different intervals from imatinib start. Seven out of 22 patients (31.8%) needed packed red cell transfusions during the follow-up. At diagnosis, patients who developed CS late chronic anemia were significantly older and had a lower Hb median level. Six out of 22 patients with CS late chronic anemia received subcutaneous recombinant alpha-erythropoietin (EPO) at the standard dosage of 40,000 IU weekly: all 6 patients achieved an erythroid response. A significantly worse event-free survival (EFS) in patients with untreated CS late chronic anemia was observed (p = 0.012). Conclusions: CS late chronic anemia during long-term treatment with imatinib is a common complication in responsive elderly patients, with worse EFS if untreated. Results with EPO are encouraging, but larger studies are warranted to define its role.
2019
Anemia; Chronic myeloid leukemia; Elderly; Imatinib; Late toxicity; Age Factors; Aged; Aged, 80 and over; Anemia; Erythrocyte Transfusion; Erythropoietin; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Treatment Outcome
01 Pubblicazione su rivista::01a Articolo in rivista
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib / Cesini, L.; Carmosino, I.; Breccia, M.; De Benedittis, D.; Mohamed, S.; De Luca, M. L.; Colafigli, G.; Molica, M.; Scalzulli, E.; Massaro, F.; Mariggio, E.; Rizzo, L.; Loglisci, M. G.; Scamuffa, M. C.; Vozella, F.; Diverio, D.; Mancini, M.; Alimena, G.; Foa, R.; Latagliata, R.. - In: ONCOLOGY RESEARCH AND TREATMENT. - ISSN 2296-5262. - 42:12(2019), pp. 660-664. [10.1159/000502801]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1416011
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact